Several studies detected abnormal mi-RNAs expression levels in childhood Acute Lymphoblastic Leukemia (ALL) with potential diagnostic value.
Treatment of adult acute lymphoblastic leukemia (ALL) has largely relied on cytotoxic chemotherapy agents borrowed from successful treatment regimens of pediatric ALL.
“A new frontier in cancer treatment” for acute lymphoblastic leukemia (ALL).
Amgen announced that data from a multicenter, randomized Phase III study evaluating the efficacy, safety and tolerability of Blincyto (blinatumomab) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) were published in The Journal of the American Medical Association (JAMA).
The primary end point of the phase III PhALLCON study (NCT03589326) was met as first-line ponatinib (Iclusig) ,from Takeda and Incyte, plus reduced-intensity chemotherapy outperformed imatinib (Gleevec) for the treatment of patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL)
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
Advances in genomic research and risk-directed therapy have led to improvements in the long-term survival and quality of life outcomes of patients with childhood acute lymphoblastic leukaemia (ALL)
Jazz Pharmaceuticals plc announced that the European Commission (EC) has granted marketing authorization for Enrylaze (JZP 458; a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase
The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions...
Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase-polymerase chain reaction...